quentli
touch
eye
nose
mouth
may
also
lead
infect
sar
typic
begin
flulik
symptom
includ
high
fever
c
higher
may
accompani
headach
muscl
ach
cough
short
breath
case
fever
may
appear
day
peopl
infect
may
develop
diarrhea
patient
sar
subsequ
develop
pneumonia
sar
patient
becom
progress
wors
develop
breath
problem
sever
may
requir
help
mechan
respir
sar
fatal
case
often
due
respiratori
failur
possibl
complic
includ
heart
liver
failur
spite
concert
global
effort
still
effect
treatment
sar
combin
antivir
drug
normal
use
treat
aidslopinavirritonavir
along
ribavirinhav
shown
clinic
studi
prevent
seriou
complic
death
sar
howev
studi
need
august
sarscov
ad
niaid
list
categori
c
prioriti
pathogen
biodefens
http
priorityhtm
fund
opportun
list
niaid
biodefens
program
http
fundinghtm
may
niaid
conven
intern
meet
sar
develop
robust
research
agenda
focus
discoveri
effect
therapi
control
diseas
number
research
goal
object
recommend
r
expand
research
effort
basic
biolog
viru
includ
studi
replic
biodivers
factor
influenc
transmiss
human
develop
anim
model
r
determin
basi
sarsassoci
immunopatholog
identifi
compon
innat
protect
immun
impact
polymorph
diseas
outcom
r
support
rapid
develop
multipl
vaccin
strategi
r
expand
capac
vitro
evalu
antivir
drug
activ
sar
identifi
viral
host
target
therapeut
intervent
r
develop
diagnost
rapid
sensit
easi
use
wide
distribut
r
defin
sar
diseas
progress
persist
correl
immun
suscept
resist
reinfect
r
expand
surveil
identifi
anim
reservoir
factor
influenc
spread
viru
assess
whether
immunocompromis
individu
children
pregnant
women
increas
risk
r
provid
research
commun
resourc
includ
opportun
upgrad
biocontain
facil
provid
standard
refer
reagent
includ
microarray
tetram
respons
need
rapid
increas
research
sar
coronaviru
niaid
initi
vigor
program
support
develop
diagnost
vaccin
therapeut
sar
http
wwwgooglecomsearch
hl
en
qniaidinfergensar
sever
major
program
niaidsupport
sar
research
includ
r
clinic
protocol
evalu
infergen
amgen
inc
engin
recombin
interferon
molecul
potent
antisarscov
activ
vitro
assay
cytopath
activ
infergen
previous
known
antihepat
c
activ
r
sever
anim
model
develop
sar
includ
mous
hamster
nonhuman
primat
none
anim
test
exhibit
clinic
diseas
intranas
administr
viru
rather
exhibit
antibodi
sarscov
clear
viru
r
niaid
biodefens
proteom
research
program
contract
identifi
target
therapeut
intervent
use
proteom
technolog
implement
seven
center
fund
http
www
niaidnihgovdmidgenomesprcdefaulthtm
r
inhibit
escap
attenu
growth
sarscov
demonstr
antisens
oligom
peptideconjug
antisens
morpholino
oligom
ppmo
design
bind
base
pair
specif
sequenc
sarscov
strain
genom
ppmo
test
capac
inhibit
product
infecti
viru
well
probe
function
conserv
viral
rna
motif
secondari
structur
ppmo
test
found
effect
administ
time
prior
peak
viral
synthesi
exert
sustain
antivir
effect
sever
viral
passag
presenc
regulatori
sequencetarget
ppmo
partial
drugresist
sarscov
mutant
aros
grew
slowli
wildtyp
sarscov
result
suggest
ppmo
compound
test
exhibit
power
therapeut
potenti
sarscov
r
supramolecular
architectur
sever
acut
respiratori
syndrom
coronaviru
reveal
electron
cryomicroscopi
recent
report
twodimension
imag
n
protein
sarscov
two
coronavirus
resolut
approxim
nm
describ
trimer
glycoprotein
protein
regist
four
underli
ribonuclear
densiti
ribonuclear
particl
display
coil
shape
releas
viral
membran
first
detail
view
coronaviru
ultrastructur
help
understand
coronaviru
assembl
pathway
r
sarscov
cystein
proteas
papainlik
proteas
plpro
identifi
structur
character
replic
sarscov
coronavirus
depend
process
replicas
polyprotein
two
cystein
proteas
one
papainlik
proteas
plpro
use
bioinformat
analys
multipl
sarscov
research
abl
identifi
put
catalyt
triad
zincbind
site
furthermor
molecular
model
plpro
suggest
deubiquitin
activ
crystal
structur
plpro
catalyt
core
elucid
demonstr
intact
zincbind
motif
catalyt
compet
activ
site
includ
ubiquitinlik
amino
termin
domain
well
overal
resembl
known
deubiquitin
enzym
site
within
catalyt
cleft
well
defin
account
strict
substraterecognit
motif
detail
understand
sarscov
plpro
enzymat
activ
domain
critic
develop
antivir
drug
better
understand
role
plpro
biogenesi
sarscov
replicas
complex
r
human
antibodi
block
human
anim
sar
virus
identifi
intern
team
investig
identifi
first
human
antibodi
neutral
differ
strain
viru
respons
outbreak
sar
research
use
mous
model
vitro
assay
test
neutral
activ
antibodi
studi
import
viral
strain
caus
outbreak
peopl
probabl
longer
exist
natur
need
proof
antibodi
effect
strain
sar
viru
isol
peopl
also
varieti
anim
strain
anim
like
sourc
reemerg
sar
viru
investig
research
spike
glycoproteinth
part
viru
bind
allow
entri
human
cellsprovid
knowledg
need
identifi
sever
human
antibodi
sar
viru
particular
research
identifi
two
human
antibodi
bind
region
sar
viru
spike
glycoprotein
call
receptorbind
domain
rbd
one
antibodi
call
found
blood
patient
infect
sar
later
recov
second
antibodi
taken
librari
human
antibodi
research
develop
blood
healthi
volunt
human
alreadi
immun
cell
express
antibodi
close
effect
neutral
sar
viru
could
fish
healthi
volunt
investig
next
solv
structur
complex
sar
rbd
show
antibodi
bind
region
rbd
allow
viru
attach
host
cell
antibodi
success
bind
sar
rbd
would
prevent
viru
attach
sar
coronaviru
receptor
outsid
human
cell
effect
neutral
test
cell
laboratori
antibodi
potent
neutral
sampl
viru
outbreak
antibodi
also
neutral
sampl
viru
taken
wild
civet
catlik
mammal
strain
viru
found
outbreak
although
somewhat
lower
potenc
discoveri
two
effect
antibodi
advantag
newli
emerg
variat
sar
coronaviru
might
insensit
neutral
one
still
suscept
result
studi
demonstr
novel
potenti
antibodybas
therapeut
sar
could
use
alon
combin
